Skip to main content
COCH
NASDAQ Industrial Applications And Services

Envoy Medical CEO Receives Significant Performance-Based Equity Awards Tied to FDA Approval

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.671
Mkt Cap
$51.733M
52W Low
$0.363
52W High
$1.89
52W Position info
85% above low
Off High info
64% below high
Rel. Volume info
34× avg
Market data snapshot near publication time

COCH sits 85% above its 52-week low of $0.363 on elevated volume (34× avg).

Summary

Envoy Medical's CEO received a new compensation package, including a salary increase and significant equity awards, with 1,000,000 restricted stock units vesting upon FDA approval of the Acclaim cochlear implant.


Key Events · Executive and Board Changes · COCH

  • CEO Compensation Updated

    CEO Brent Lucas's base salary was increased to $420,000 per year, with eligibility for a cash bonus targeted at $105,000 based on strategic performance goals for 2026 and 2027.

  • Significant Stock Option Grant

    Mr. Lucas was granted 1,000,000 stock options exercisable at $0.634 per share, vesting over a four-year period.

  • Performance-Based RSU Grant

    Mr. Lucas also received 1,000,000 restricted stock units (RSUs) that will vest upon official FDA approval of the company's Acclaim cochlear implant, provided approval occurs by June 18, 2030.

  • Strategic Incentive Alignment

    The equity awards, particularly the RSUs, directly link the CEO's compensation to the critical FDA approval milestone for the Acclaim cochlear implant, a key product for the company's future.


Analysis · COCH · Industrial Applications And Services

Envoy Medical's CEO, Brent Lucas, has been granted a substantial equity package, including 1,000,000 stock options and 1,000,000 restricted stock units (RSUs). The RSUs are particularly noteworthy as they vest only upon FDA approval of the company's Acclaim cochlear implant, a critical milestone for the company, especially given its ongoing 'going concern' doubts. This package, valued at over $1.3 million (approximately 2.5% of the company's market cap), strongly aligns the CEO's incentives with the successful commercialization of its key product, which is crucial for the company's long-term viability.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COCH was trading at $0.67 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $51.7M. The 52-week trading range was $0.36 to $1.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COCH - Latest Insights

COCH
Nov 05, 2026, 1:56 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.05
Real-time Price: $6.74 info
Change: -$0.310 (-4%) info
Market Cap: $52.125M info
COCH
Nov 05, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.12
Real-time Price: $6.74 info
Change: -$0.385 (-5%) info
Market Cap: $52.125M info
COCH
Aug 31, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $6.74 info
Change: Reverse Stock Split info
Market Cap: $52.125M info
COCH
Aug 19, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.740
Real-time Price: $6.74 info
Change: Reverse Stock Split info
Market Cap: $52.125M info
COCH
Aug 10, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.705
Real-time Price: $6.74 info
Change: Reverse Stock Split info
Market Cap: $52.125M info